Cardinal Health (CAH) Earnings Date & Reports

Key Takeaways

• Non-GAAP EPS of $2.91 surged 40% year-over-year, handily beating the consensus estimate of approximately $2.41.
• Revenue rose 6% to $63.7 billion, missing the consensus estimate of roughly $65.2 billion but reflecting solid demand across the pharmaceutical distribution business.
• Full-year non-GAAP EPS reached $11.26, up 37% from fiscal 2025, capping what management called a standout year.
• Fiscal 2027 EPS guidance of $12.40 to $12.60 came in well above the $12.05 analyst consensus, implying 13% to 15% growth.
• The quarter included a one-time $0.31 per share benefit from IEEPA (International Emergency Economic Powers Act) tariff refunds in the medical products segment.
• Shares rose approximately 3% following the release, extending year-to-date gains above 15%.

Earnings Context and Why It Matters

Cardinal Health's fourth-quarter and full-year fiscal 2026 results land at a pivotal moment for the healthcare distribution giant. The company has been executing a multi-year strategic transformation aimed at improving margins, streamlining its Global Medical Products and Distribution (GMPD) segment, and accelerating growth in higher-margin specialty and home-health businesses. This earnings report matters because it provides a report card on that turnaround and sets the tone for fiscal 2027. With the stock up more than 60% over the past twelve months and trading at elevated valuation multiples, investors were looking for confirmation that the operational momentum is sustainable — and the guidance provided a strong affirmative signal.

Reported Results

Cardinal Health reported fourth-quarter fiscal 2026 revenue of $63.7 billion, up 6% from $60.2 billion in the prior-year period. While the top line came in below the analyst consensus of approximately $65.2 billion, the bottom-line performance more than compensated. Non-GAAP diluted earnings per share (EPS) reached $2.91, a 40% increase from $2.08 a year ago and a comfortable beat against the $2.41 consensus estimate. On a GAAP (Generally Accepted Accounting Principles) basis, diluted EPS was $1.70, up 70% from $1.00 in the prior-year quarter.

The Pharmaceutical and Specialty Solutions segment — by far the largest — posted revenue of $58.8 billion, up 6%, with segment profit climbing 21% to $645 million. Growth was fueled by strong brand and specialty pharmaceutical demand, positive generics program performance, and specialty revenue expansion exceeding 25% for the full year. The Global Medical Products and Distribution segment recorded revenue of $3.1 billion, down 2%, though segment profit jumped to $150 million from $70 million, boosted by the one-time $100 million net benefit from anticipated IEEPA tariff refunds. Excluding that item, GMPD profit would have been $50 million. The Other segment — encompassing Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics — generated $1.7 billion in revenue, up 7%, with segment profit rising 14% to $183 million.

For the full fiscal year 2026, total revenue reached $254.2 billion (up 14%), non-GAAP operating earnings grew 30% to $3.6 billion, and adjusted free cash flow hit $5.0 billion. The company returned $1.4 billion to shareholders through share repurchases, and the board authorized an additional $5.0 billion buyback program.

AI Screener

For investors seeking to identify opportunities across earnings seasons and beyond, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated trading signals. Whether scanning for breakout candidates, earnings momentum plays, or fundamentally strong companies within the healthcare distribution sector, the AI Screener streamlines the research process and helps surface ideas that manual screening might overlook. Explore the AI Screener to see how intelligent filtering can sharpen your market analysis.

Market Reaction and Investor Sentiment

Cardinal Health shares rose approximately 3% in the trading session following the August 11 release, reflecting a positive investor reception to the earnings beat and, more importantly, the fiscal 2027 guidance range that exceeded consensus expectations. The revenue miss was largely overlooked, as it primarily reflected pass-through dynamics in the pharmaceutical distribution business — where top-line growth can be influenced by drug pricing adjustments and product mix shifts rather than underlying demand weakness. Sentiment was further supported by the $5.0 billion increase in share repurchase authorization, which signals management's confidence in sustained free cash flow generation. Heading into the report, the stock had rallied over 60% in the preceding twelve months, and the results largely validated the premium valuation by demonstrating durable earnings momentum across all five operating segments.

Forward Outlook and Key Factors to Monitor

Cardinal Health enters fiscal 2027 with considerable momentum. The company issued non-GAAP EPS guidance of $12.40 to $12.60, representing 13% to 15% growth off an adjusted fiscal 2026 baseline that strips out the non-recurring IEEPA tariff refund. This guidance sits above the company's long-term target of 12% to 14% EPS growth and comfortably ahead of the $12.05 Wall Street consensus.

Several dynamics will shape the year ahead. In the Pharmaceutical and Specialty Solutions segment, management expects revenue growth of 3% to 5% and profit growth of 8% to 11%, with continued contributions from specialty pharmaceuticals, the generics program, and recent tuck-in acquisitions. The GMPD segment is projected to deliver $200 million to $220 million in profit — a meaningful step up from the adjusted fiscal 2026 baseline of $158 million — and revenue growth of 2% to 4%. The higher-margin growth businesses grouped under "Other" are expected to lead with revenue growth of 11% to 13% and profit growth of 15% to 18%.

Key factors investors should monitor include the trajectory of GMPD's turnaround, which remains in its early stages of margin recovery; the sustainability of specialty pharmaceutical demand growth, which management expects to moderate from fiscal 2026's above-25% pace; the impact of Inflation Reduction Act provisions on pharmaceutical pricing and segment revenue; and the company's ability to deploy its substantial cash position and expanded buyback authorization effectively. Tariff-related cost pressures and geopolitical risks — including potential fuel and commodity cost increases from ongoing conflicts — also warrant attention, as management noted these could push GMPD toward the lower end of guidance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations